Gilead Sciences Inc (GILD)
67.72
-0.14
(-0.21%)
USD |
NASDAQ |
May 17, 16:00
67.74
+0.02
(+0.03%)
After-Hours: 20:00
Gilead Sciences Enterprise Value: 104.76B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 104.76B |
| May 16, 2024 | 104.94B |
| May 15, 2024 | 103.88B |
| May 14, 2024 | 104.67B |
| May 13, 2024 | 104.54B |
| May 10, 2024 | 102.57B |
| May 09, 2024 | 100.85B |
| May 08, 2024 | 101.27B |
| May 07, 2024 | 101.95B |
| May 06, 2024 | 102.05B |
| May 03, 2024 | 101.10B |
| May 02, 2024 | 101.78B |
| May 01, 2024 | 102.01B |
| April 30, 2024 | 101.62B |
| April 29, 2024 | 102.62B |
| April 26, 2024 | 101.97B |
| April 25, 2024 | 101.78B |
| April 24, 2024 | 104.04B |
| April 23, 2024 | 103.98B |
| April 22, 2024 | 103.88B |
| April 19, 2024 | 103.64B |
| April 18, 2024 | 102.89B |
| April 17, 2024 | 103.85B |
| April 16, 2024 | 104.33B |
| April 15, 2024 | 104.87B |
| Date | Value |
|---|---|
| April 12, 2024 | 105.27B |
| April 11, 2024 | 106.00B |
| April 10, 2024 | 105.34B |
| April 09, 2024 | 107.61B |
| April 08, 2024 | 106.96B |
| April 05, 2024 | 107.16B |
| April 04, 2024 | 107.12B |
| April 03, 2024 | 108.79B |
| April 02, 2024 | 110.29B |
| April 01, 2024 | 111.27B |
| March 31, 2024 | 111.73B |
| March 28, 2024 | 108.98B |
| March 27, 2024 | 108.68B |
| March 26, 2024 | 107.93B |
| March 25, 2024 | 108.14B |
| March 22, 2024 | 108.18B |
| March 21, 2024 | 108.78B |
| March 20, 2024 | 109.89B |
| March 19, 2024 | 109.18B |
| March 18, 2024 | 108.99B |
| March 15, 2024 | 109.53B |
| March 14, 2024 | 110.04B |
| March 13, 2024 | 112.19B |
| March 12, 2024 | 111.12B |
| March 11, 2024 | 111.42B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
76.35B
Minimum
Dec 30 2020
131.76B
Maximum
Dec 08 2022
102.74B
Average
104.53B
Median
Enterprise Value Benchmarks
| Bristol-Myers Squibb Co | 135.32B |
| Merck & Co Inc | 360.94B |
| Pfizer Inc | 219.35B |
| AbbVie Inc | 349.85B |
| Xilio Therapeutics Inc | 8.100M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.17B |
| Revenue (Quarterly) | 6.686B |
| Total Expenses (Quarterly) | 6.877B |
| EPS Diluted (Quarterly) | -3.34 |
| Gross Profit Margin (Quarterly) | 76.79% |
| Profit Margin (Quarterly) | -62.37% |
| Earnings Yield | 0.53% |
| Operating Earnings Yield | 7.57% |
| Normalized Earnings Yield | 5.762 |